Nektar Therapeutics
NKTR | NASDAQ
$36.44
-$0.83 (-2.23%)
At close: Nov 16, 2026, 4:00 PM ET
$36.29
-$0.15 (-0.41%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Nektar Therapeutics Company Profile
Company profile explainedCompany Profile
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Howard W. Robin | Chief Executive Officer, President & Director |
| Linda Rubinstein | Chief Financial Officer and Principal Financial & Accounting Officer |
| Robert Bacci | Chief People Officer and Head of Quality & Facilities |
| Elizabeth Zhang | VP of Legal, Corporate Counsel & Secretary |
| Jason Barnard | Chief Accounting Officer |
| Jennifer Ruddock | Chief Business Officer |
| Jonathan Zalevsky | Senior Vice President and Chief Research & Development Officer |
| Ken Franke | Senior Vice President of Biologics Process Development & Manufacturing |
| Mary Tagliaferri | Chief Medical Officer |
| Spilios Asimakopoulos | Vice President of Commercial Strategy & Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | S-8 | Filing |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 8-K | Current Report |
Nektar Therapeutics
| Country | United States |
| IPO Date | May 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Howard W. Robin |
Contact Details
455 Mission Bay Boulevard South San Francisco,
California 94158 United States
Stock Details
| Ticker Symbol | NKTR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000906709 |
| CUSIP Number | 640268306 |
| ISIN Number | US6402683063 |
| SIC Code | 2834 |
Recent News
- 3 days ago / zacks.comNKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down
- 3 days ago / seekingalpha.comNektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
- 4 days ago / marketbeat.comWhat Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
- 4 days ago / zacks.comNektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates
- 4 days ago / prnewswire.comNektar Therapeutics Announces Third Quarter 2026 Financial Results
- 5 days ago / prnewswire.comNektar Therapeutics to Participate in Two Investor Conferences in November
- 18 days ago / seekingalpha.comNektar Therapeutics: Focus Returns To The Strengths Of The Company
- 19 days ago / zacks.comNektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
- 20 days ago / prnewswire.comNektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
- 2 months ago / seekingalpha.comNektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More
Add to Watchlist
Select watchlists to add or remove NKTR